Slate Bio focuses on advanced T regulatory (T reg) cell therapy aimed at treating autoimmune diseases. Their innovative approach leverages the unique properties of T reg cells, which play a crucial role in maintaining immune tolerance and preventing excessive immune responses that can lead to autoimmune conditions. By enhancing the function and proliferation of these cells, Slate Bio aims to develop therapies that can effectively modulate the immune system and provide long-lasting relief for patients suffering from various autoimmune disorders.

The company is actively developing a pipeline of products that utilize this T reg therapy technology. Their research emphasizes the potential of these therapies to not only alleviate symptoms but also address the underlying causes of autoimmune diseases. By harnessing the power of T reg cells, Slate Bio is positioned to make significant advancements in the treatment landscape for patients with challenging autoimmune conditions, offering hope for improved health outcomes and quality of life.

United States

Slate Bio is a Virginia-based biopharmaceutical company that develops and commercializes T cell therapies for the treatment of autoimmune and inflammatory diseases. 

Slate Bio

Company Details